Pilot evaluation of ivacaftor for chronic bronchitis.
作者信息
Solomon George M, Hathorne Heather, Liu Bo, Raju S Vamsee, Reeves Ginger, Acosta Edward P, Dransfield Mark T, Rowe Steven M
机构信息
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA.
Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA.
出版信息
Lancet Respir Med. 2016 Jun;4(6):e32-3. doi: 10.1016/S2213-2600(16)30047-9. Epub 2016 May 16.
Abstract
摘要
相似文献
1
Pilot evaluation of ivacaftor for chronic bronchitis.依伐卡托治疗慢性支气管炎的初步评估。
Lancet Respir Med. 2016 Jun;4(6):e32-3. doi: 10.1016/S2213-2600(16)30047-9. Epub 2016 May 16.
2
Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement.依伐卡托治疗的囊性纤维化患者虽无短期临床改善，但仍获得长期益处。
Am J Respir Crit Care Med. 2018 Jun 1;197(11):1483-1486. doi: 10.1164/rccm.201710-2046LE.
3
The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.依伐卡托治疗12个月对苏格兰患有G551D突变的囊性纤维化儿科患者的影响：一项综述。
Arch Dis Child. 2018 Jan;103(1):68-70. doi: 10.1136/archdischild-2015-310420. Epub 2016 Jun 10.
4
Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor.
Eur Respir J. 2016 Jul;48(1):249-52. doi: 10.1183/13993003.01918-2015. Epub 2016 May 26.
5
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.依伐卡托特治疗携带 Arg117His-CFTR 突变的囊性纤维化患者的疗效和安全性：一项双盲、随机对照试验。
Lancet Respir Med. 2015 Jul;3(7):524-33. doi: 10.1016/S2213-2600(15)00201-5. Epub 2015 Jun 9.
6
Potentiators for cystic fibrosis - targeting the underlying molecular defect.囊性纤维化的增效剂——针对潜在分子缺陷
Paediatr Respir Rev. 2015 Jun;16(3):162-4. doi: 10.1016/j.prrv.2015.04.003. Epub 2015 Apr 20.
7
A safety evaluation of ivacaftor for the treatment of cystic fibrosis.依伐卡托治疗囊性纤维化的安全性评估。
Expert Opin Drug Saf. 2016 May;15(5):709-15. doi: 10.1517/14740338.2016.1165666. Epub 2016 Apr 7.
8
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.鲁马卡托和依伐卡托用于囊性纤维化患者的治疗：当前证据与未来前景
Ther Adv Respir Dis. 2015 Dec;9(6):313-26. doi: 10.1177/1753465815601934. Epub 2015 Sep 28.
9
Treating Specific Variants Causing Cystic Fibrosis.治疗导致囊性纤维化的特定变体。
JAMA. 2017 Dec 5;318(21):2130-2131. doi: 10.1001/jama.2017.16823.
10
Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.肠道电流测量可检测出接受依伐卡托治疗的携带G551D突变的囊性纤维化患者中突变型CFTR的激活情况。
Am J Respir Crit Care Med. 2015 Nov 15;192(10):1252-5. doi: 10.1164/rccm.201507-1271LE.
引用本文的文献
1
Therapeutic strategies to reverse cigarette smoke-induced ion channel and mucociliary dysfunction in COPD airway epithelial cells.逆转香烟烟雾诱导的慢性阻塞性肺疾病气道上皮细胞离子通道和黏液纤毛功能障碍的治疗策略。
Am J Physiol Lung Cell Mol Physiol. 2025 Apr 1;328(4):L571-L585. doi: 10.1152/ajplung.00258.2024. Epub 2025 Mar 17.
2
CFTR Modulators for the Treatment of COPD: The Jury Is Still Out!用于治疗慢性阻塞性肺疾病的囊性纤维化跨膜传导调节因子调节剂：尚无定论！
Am J Respir Crit Care Med. 2024 Nov 5;211(5):687-9. doi: 10.1164/rccm.202409-1878ED.
3
Multi-modal transcriptomic analysis reveals metabolic dysregulation and immune responses in chronic obstructive pulmonary disease.多模态转录组学分析揭示慢性阻塞性肺疾病中的代谢失调和免疫反应。
Sci Rep. 2024 Sep 30;14(1):22699. doi: 10.1038/s41598-024-71773-w.
4
Ivacaftor for Chronic Obstructive Pulmonary Disease - Results from a Phase 2, Randomized Controlled Trial.依伐卡托治疗慢性阻塞性肺疾病——一项2期随机对照试验的结果
Am J Respir Crit Care Med. 2024 Sep 24;211(5):823-31. doi: 10.1164/rccm.202407-1302OC.
5
Multimorbidities in COPD are Associated With Increased Exacerbations and Health Care Resource Utilization in Real-World Patients from a U.S. Database.慢性阻塞性肺疾病（COPD）的多种合并症与美国数据库中真实世界患者的急性加重增加及医疗资源利用增加相关。
Chronic Obstr Pulm Dis. 2024 Sep 27;11(5):472-481. doi: 10.15326/jcopdf.2024.0515.
6
in cystic fibrosis children and adolescents: overall survival and immune alterations.在囊性纤维化的儿童和青少年中：总体生存率和免疫改变。
Front Cell Infect Microbiol. 2024 Jul 1;14:1374318. doi: 10.3389/fcimb.2024.1374318. eCollection 2024.
7
Therapeutic Targets and Precision Medicine in COPD: Inflammation, Ion Channels, Both, or Neither?COPD 的治疗靶点和精准医学：炎症、离子通道，还是两者兼有？
Int J Mol Sci. 2023 Dec 11;24(24):17363. doi: 10.3390/ijms242417363.
8
Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages.CFTR 调节剂对 CF 和非 CF 巨噬细胞吞噬、代谢和炎症特征的比较影响。
Sci Rep. 2023 Jul 25;13(1):11995. doi: 10.1038/s41598-023-38300-9.
9
Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities.老年 COPD 患者的药物治疗：挑战与机遇。
Drugs Aging. 2023 Jul;40(7):605-619. doi: 10.1007/s40266-023-01038-0. Epub 2023 Jun 14.
10
Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond.慢性阻塞性肺疾病中的囊性纤维化跨膜电导调节因子：呼吸上皮细胞内外的作用。
Eur Respir J. 2023 Apr 1;61(4). doi: 10.1183/13993003.01307-2022. Print 2023 Apr.
本文引用的文献
1
Recovery of Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction after Smoking Cessation.戒烟后获得性囊性纤维化跨膜传导调节因子功能障碍的恢复
Am J Respir Crit Care Med. 2015 Dec 15;192(12):1521-4. doi: 10.1164/rccm.201502-0396LE.
2
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.依伐卡托特治疗携带 Arg117His-CFTR 突变的囊性纤维化患者的疗效和安全性：一项双盲、随机对照试验。
Lancet Respir Med. 2015 Jul;3(7):524-33. doi: 10.1016/S2213-2600(15)00201-5. Epub 2015 Jun 9.
3
Physiologic characterization of the chronic bronchitis phenotype in GOLD grade IB COPD.COPD 中 GOLD 分级 IB 级慢性支气管炎表型的生理学特征。
Chest. 2015 May;147(5):1235-1245. doi: 10.1378/chest.14-1491.
4
Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.囊性纤维化跨膜传导调节因子增强剂依伐卡托在G551D介导的囊性纤维化中的临床机制
Am J Respir Crit Care Med. 2014 Jul 15;190(2):175-84. doi: 10.1164/rccm.201404-0703OC.
5
Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary disease.慢性阻塞性肺疾病中 CFTR 依赖性β-肾上腺素能汗液分泌的获得性缺陷。
Respir Res. 2014 Feb 25;15(1):25. doi: 10.1186/1465-9921-15-25.
6
Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function.香烟烟雾会导致囊性纤维化跨膜电导调节因子功能的全身缺陷。
Am J Respir Crit Care Med. 2013 Dec 1;188(11):1321-30. doi: 10.1164/rccm.201304-0733OC.
7
Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.COPD 患者下呼吸道中获得性囊性纤维化跨膜电导调节剂功能障碍。
Chest. 2013 Aug;144(2):498-506. doi: 10.1378/chest.13-0274.
8
A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease.吸烟相关肺部疾病中获得性囊性纤维化跨膜电导调节因子功能障碍的药物治疗方法。
PLoS One. 2012;7(6):e39809. doi: 10.1371/journal.pone.0039809. Epub 2012 Jun 29.
9
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.囊性纤维化跨膜电导调节因子增效剂治疗囊性纤维化跨膜电导调节因子 G551D 突变患者。
N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.
10
Factors associated with bronchiectasis in patients with COPD.与 COPD 患者支气管扩张相关的因素。
Chest. 2011 Nov;140(5):1130-1137. doi: 10.1378/chest.10-1758. Epub 2011 May 5.
Zotero 插件